Drugs & Therapy Perspectives

, Volume 17, Issue 3, pp 10–13 | Cite as

Drug interactions with HIV protease inhibitors: some useful, others problematic

Drug reactions and interactions
  • 10 Downloads

Keywords

Acromegaly Clarithromycin Ritonavir Efavirenz Indinavir 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999 Feb; 20(2): 147–69PubMedCrossRefGoogle Scholar
  2. 2.
    van Cleef GF, Fisher EJ, Polk RE. Drug interaction potential with inhibitors of HIV protease. Pharmacotherapy 1997; 17: 774–8PubMedGoogle Scholar
  3. 3.
    Preston SL, Postelnick M, Purdy BD, et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. AIDS 1998; 12: 228–30PubMedGoogle Scholar
  4. 4.
    Figgit D, Plosker G. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection. Drugs 2000 Aug; 60(2): 481–516CrossRefGoogle Scholar
  5. 5.
    Eagling VA, Black DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors ritonavir, saquinavir, and indinavir. Br J Clin Pharmacol 1997; 44: 190–4PubMedCrossRefGoogle Scholar
  6. 6.
    von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106–111Google Scholar
  7. 7.
    Plosker G, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 1999 Dec; 58(6): 1165–203PubMedCrossRefGoogle Scholar
  8. 8.
    Bardsley-Elliot, Plosker G. Nelfinavir: an update on its use in HIV infection. Drugs 2000 Mar; 59(3): 581–620PubMedCrossRefGoogle Scholar
  9. 9.
    Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 2784–91PubMedGoogle Scholar
  10. 10.
    Cox SR, Schneck DW, Herman BD, et al. Delavirdine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug-interaction study in healthy adult volunteers [abstract no. 345]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)Google Scholar
  11. 11.
    Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998; 47: 1–58Google Scholar

Copyright information

© Adis International Limited 2001

Personalised recommendations